1. 124PAssociation of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). (23rd October 2018) Authors: Miller-Phillips, L; Fischer von Weikersthal, L; Kaiser, F; Al-Batran, S-E; Heintges, T; Neureiter, D; Kahl, C; Kullmann, F; Moehler, M; Scheithauer, W; Vazart, C; Fontaine, K; Held, S; Modest, D P; Neumann, J; Jung, A; Kirchner, T; Heinemann, V; Stintzing, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. (14th November 2019) Authors: Stintzing, S; Wirapati, P; Lenz, H -J; Neureiter, D; Fischer von Weikersthal, L; Decker, T; Kiani, A; Kaiser, F; Al-Batran, S; Heintges, T; Lerchenmüller, C; Kahl, C; Seipelt, G; Kullmann, F; Moehler, M; Scheithauer, W; Held, S; Modest, D P; Jung, A; Kirchner, T Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Gender medicine and oncology: report and consensus of an ESMO workshop. (15th October 2019) Authors: Wagner, A D; Oertelt-Prigione, S; Adjei, A; Buclin, T; Cristina, V; Csajka, C; Coukos, G; Dafni, U; Dotto, G -P; Ducreux, M; Fellay, J; Haanen, J; Hocquelet, A; Klinge, I; Lemmens, V; Letsch, A; Mauer, M; Moehler, M; Peters, S; Özdemir, B C Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1914 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Novel ways to sensitise gastrointestinal cancer to apoptosis. Issue 7 (11th June 2009) Authors: Schulze-Bergkamen, H; Weinmann, A; Moehler, M; Siebler, J; Galle, P R Journal: Gut Issue: Volume 58:Issue 7(2009) Page Start: 1010 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-010Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program. (20th June 2018) Authors: Moehler, M; Maderer, A; Thuss-Patience, P; Brenner, B; Hecker, J; Muñoz, F Longo; Meiler, J; Ettrich, T; Hofheinz, R; Al-Batran, S; Vogel, A; Mueller, L; Lutz, M; Borchert, K; Greil, R; Alsina, M; Karatas, A; Van Cutsem, E; Keller, R; Larcher-Senn, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗